| Literature DB >> 32288789 |
Jiang Hu1, Yan Song2, Xia Mao1, Zhen-Ji Wang3, Qin-Jie Zhao4.
Abstract
A phytochemical investigation of the ethanol extract of Toona sinensis (A. Juss.) Roem resulted in the isolation of ten new limonoids, toonasinenines A-J (1-10), together with two known compounds, toonafolin (11) and toonacilianin D (12). Their structures were determined by spectroscopic analyses. The isolated components were evaluated in vitro for radical scavenging potential using ABTS⋅+ and DPPH test, anti-inflammatory activities for Cox-1 and Cox-2, and cytotoxicies against nine tumour cell lines (A549, BGC-823, CHG-5, HCT15, HeLa, HepG2, MDA-MB-231, SHG-44 and SGC-7901 cells). As a result, 4, 5 and 7-10 showed potent radical scavenging activities, while limonoids 1-4 and 11 exhibited significant anti-inflammatory and cytotoxic potential.Entities:
Keywords: Anti-inflammatory; Cytotoxic activities; Limonoids; Meliaceae; Radical scavenging; Toona sinensis
Year: 2015 PMID: 32288789 PMCID: PMC7104945 DOI: 10.1016/j.jff.2015.10.009
Source DB: PubMed Journal: J Funct Foods ISSN: 1756-4646 Impact factor: 4.451
Fig. 1The structures of limonoids 1–12.
1H NMR (400 MHz) and 13C NMR (100 MHz) data for compounds 1, 4–7 and 9: δ in ppm in CD3OD (multiplicities, J in Hz).
| No. | 1 | 4 | 5 | 6 | 7 | 9 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 3.80, dd (11.4, 5.0) | 85.5 | 107.5 | 7.30, d (10.7) | 155.7 | 3.23, d (4.3) | 57.9 | 6.80, d (10.0) | 152.6 | 6.28, d (11.8) | 150.1 | |
| 2α | 2.95, dd (15.8, 11.4) | 42.9 | 2.66, dd (14.2, 13.7) | 44.5 | 6.01, d (10.7) | 127.3 | 58.2 | 5.97, d (10.0) | 124.6 | 5.97, d (11.8) | 121.5 | |
| 2β | 2.66, overlapped | 2.01, dd (14.2, 4.4) | 3.11, m | |||||||||
| 3 | 208.8 | 4.34, dd (13.7, 4.4) | 70.8 | 207.1 | 3.69, d (2.8) | 74.0 | 204.8 | 166.7 | ||||
| 4 | 53.8 | 95.5 | 59.5 | 39.4 | 46.5 | 83.6 | ||||||
| 5 | 2.66, overlapped | 52.1 | 84.0 | 2.54, s | 48.5 | 2.34, s | 49.8 | 2.46, s | 48.8 | 2.48, s | 51.2 | |
| 6α | 2.63, dd (16.5, 1.8) | 32.9 | 3.89, s | 78.3 | 4.61, s | 72.5 | 4.42, s | 72.8 | 4.69, s | 71.2 | 4.69, s | 70.1 |
| 6β | 3.28, dd (16.5, 8.6) | |||||||||||
| 7 | 173.8 | 176.5 | 178.4 | 182.2 | 177.1 | 176.7 | ||||||
| 8 | 76.7 | 76.7 | 139.0 | 78.0 | 77.8 | 77.0 | ||||||
| 9 | 2.73, d (11.5) | 63.5 | 3.17, d (12.5) | 55.9 | 2.68, d (11.5) | 57.5 | 2.61, d (11.5) | 46.7 | 2.33, d (11.5) | 44.9 | 2.39, d (11.5) | 52.1 |
| 10 | 49.0 | 56.4 | 42.0 | 41.7 | 44.1 | 49.1 | ||||||
| 11α | 76.5 | 74.5 | 70.8 | 2.13, m | 35.3 | 2.21, m | 27.7 | 1.79, m | 24.7 | |||
| 11β | 3.95, m | 4.27, m | 5.16, m | 2.02, m | 2.07, m | 1.39, m | ||||||
| 12α | 1.62, dd (15.5, 5.6) | 41.0 | 1.55 dd (13.0, 6.6) | 46.7 | 1.86, dd (15.5, 11.6) | 42.8 | 77.2 | 62.1 | 1.55, dd (15.5, 11.2) | 35.3 | ||
| 12β | 2.44, dd (15.5, 11.6) | 2.36, dd (13.0, 10.6) | 1.92, dd (15.5, 5.6) | 4.07, dd (13.5, 10.8) | 4.08, dd (15.5, 11.6) | 1.94, dd (15.5, 5.4) | ||||||
| 13 | 41.6 | 42.9 | 45.4 | 47.8 | 45.9 | 41.0 | ||||||
| 14 | 74.3 | 73.8 | 73.3 | 76.5 | 74.6 | 74.6 | ||||||
| 15 | 3.46, s | 54.9 | 3.58, s | 57.2 | 4.06, s | 62.1 | 3.54, s | 56.9 | 3.47, s | 54.2 | 3.46, s | 54.4 |
| 16α | 1.81, dd (13.2, 6.6) | 31.3 | 1.87, dd (13.2, 6.6) | 32.5 | 2.00, dd (13.4, 11.0) | 32.1 | 1.89, dd (13.4, 11.2) | 33.4 | 1.79, m | 31.7 | 1.80, dd (13.2, 10.9) | 31.8 |
| 16β | 2.28, dd (13.2, 11.2) | 2.21, dd (13.2, 11.2) | 2.19, dd (13.4, 6.5) | 2.20, dd (13.4, 6.4) | 2.31, m | 2.25, dd (13.2, 6.4) | ||||||
| 17 | 2.76, dd (11.2, 6.6) | 41.2 | 2.74, dd (11.2, 6.6) | 43.6 | 2.63, dd (11.0, 6.5) | 41.4 | 2.73, dd (11.2, 6.4) | 44.0 | 2.77, dd (10.8, 6.4) | 41.3 | 2.74, dd (10.9, 6.4) | 41.3 |
| 18 | 1.05, s | 19.6 | 1.07, s | 23.9 | 0.71, s | 19.9 | 0.93, s | 16.6 | 0.84, s | 15.3 | 0.97, s | 22.7 |
| 19 | 1.08, s | 21.8 | 1.44, s | 13.5 | 1.22, s | 21.3 | 1.57, s | 19.4 | 1.76, s | 19.1 | 1.45, s | 21.0 |
| 20 | 122.7 | 124.9 | 124.8 | 125.4 | 123.3 | 123.0 | ||||||
| 21 | 7.15, br s | 139.3 | 7.32, s | 141.3 | 7.21, s | 141.4 | 7.24, s | 141.2 | 7.08, s | 139.0 | 7.13, s | 139.2 |
| 22 | 6.21, br s | 110.5 | 6.35, br s | 112.7 | 6.25, br s | 112.6 | 6.40, br s | 112.9 | 6.22, br s | 110.8 | 6.17, br s | 110.6 |
| 23 | 7.41, s | 143.1 | 7.42, br s | 144.4 | 7.44, br s | 144.9 | 7.39, br s | 144.3 | 7.35, br s | 142.7 | 7.36, br s | 142.9 |
| 28 | 1.02, s | 19.8 | 1.55, s | 15.8 | 1.07, s | 22. 4 | 0.85, s | 30.5 | 1.42, s | 24.8 | 1.46, s | 30.2 |
| 29a | 4.77, d (11.2) | 66.5 | 1.41, s | 26.2 | 1.12, s | 23.0 | 1.08, s | 21.9 | 1.70, s | 24.4 | ||
| 29b | 4.41, d (11.2) | |||||||||||
| 30a | 1.25, s | 20.3 | 1.29, s | 23.7 | 5.45, s | 121.6 | 1.25, s | 21.7 | 1.35, s | 21.7 | 1.34, s | 22.1 |
| 30b | 5.33, s | |||||||||||
| 7-OMe | 3.78, s | 52.2 | 3.67, s | 53.3 | 3.71, s | 53.4 | 3.78, s | 53.1 | 3.78, s | 52.8 | ||
| Ac | 2.23, s | 169.8 | 1.99, s | 171.7 | ||||||||
| 20.8 | 21.4 |
In vitro free radical scavenging and anti–inflammatory activities of compounds 1–12.
| Compounds | Free radical scavenging activity | Anti-inflammatory activity | ||
|---|---|---|---|---|
| DPPH IC50 | ABTS⋅+ IC50 | COX–1 | COX–2 | |
|
| – | – | 88.1 | 35.6 |
|
| – | – | 92.7 | 39.3 |
|
| – | – | 91.1 | 40.2 |
|
| 104.0 | 52.2 | 95.2 | 40.1 |
|
| 62.1 | 124.7 | 44.3 | 21.4 |
|
| 244.7 | 256.1 | 53.1 | 24.4 |
|
| 59.2 | 119.8 | <0 | <0 |
|
| 51.3 | 109.7 | <0 | <0 |
|
| 71.0 | 160.1 | <0 | <0 |
| 73.1 | 167.3 | 30.2 | 19.7 | |
| – | – | 89.8 | 37.6 | |
| – | – | 44.3 | 20.7 | |
| SC–560 | 63.5 | |||
| NS–398 | 97.0 | |||
| Trolox | 42.8 | 80.1 | ||
All compounds and reference drug are expressed as IC50 values in µM. (–) No activity.
Percent inhibition (all compounds and reference drugs concentration: 100 µM).
Fig. 2Key HMBC () correlations of compounds 1, 5, 6, 8 and 10.
Cytotoxicities of compounds 1–12 against nine human tumour cell lines (IC50 ± SD, µM).
| Compounds | Cell lines | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| A-549 | BGC-823 | CHG-5 | HCT15 | HeLa | HepG2 | MDA-MB-231 | SGC-7901 | SHG-44 | |
| 13.3 ± 3.0 | – | 14.6 ± 4.6 | 14.7 ± 4.3 | 14.0 ± 4.3 | 13.9 ± 3.7 | 14.2 ± 4.0 | 13.1 ± 4.9 | – | |
| 5.7 ± 2.7 | 33.7 ± 7.8 | 5.0 ± 2.1 | 5.7 ± 2.3 | 6.2 ± 2.7 | 5.5 ± 1.6 | 6.0 ± 1.1 | 6.0 ± 2.1 | – | |
| 9.7 ± 7.4 | – | 8.3 ± 5.7 | 10.1 ± 6.4 | 8.1 ± 5.1 | 9.1 ± 8.8 | 9.4 ± 7.3 | 9.4 ± 8.1 | – | |
| 2.3 ± 0.6 | 27.9 ± 9.6 | 2.8 ± 0.7 | 2.6 ± 0.5 | 2.9 ± 0.8 | 3.0 ± 1.1 | 2.7 ± 0.9 | 2.1 ± 0.7 | 44.9 ± 10.3 | |
| 20.4 ± 4.6 | – | 19.9 ± 5.3 | 21.5 ± 6.8 | 23.6 ± 5.0 | 23.4 ± 4.5 | 21.0 ± 3.5 | 21.1 ± 4.6 | – | |
| 23.3 ± 5.0 | – | 23.9 ± 6.2 | 24.6 ± 6.1 | 24.7 ± 7.1 | 24.0 ± 5.3 | 22.4 ± 4.4 | 24.2 ± 5.0 | – | |
| 18.4 ± 4.9 | – | 19.5 ± 5.3 | 18.4 ± 5.7 | 21.6 ± 5.3 | 21.7 ± 5.0 | 20.8 ± 5.3 | 19.9 ± 4.0 | – | |
| 34.8 ± 7.2 | – | 31.2 ± 8.6 | 33.2 ± 8.7 | 31.4 ± 7.1 | 31.6 ± 6.1 | 33.2 ± 8.1 | 33.6 ± 7.9 | – | |
| 44.3 ± 8.2 | 18.6 ± 4.0 | – | – | – | 43.2 ± 10.1 | – | 39.1 ± 9.7 | 28.0 ± 5.3 | |
| – | 22.7 ± 4.1 | – | 49.7 ± 9.1 | – | 46.7 ± 9.8 | – | – | 31.4 ± 7.4 | |
| 9.7 ± 2.7 | 47.1 ± 13.1 | 9.6 ± 1.3 | 11.2 ± 3.4 | 9.0 ± 2.1 | 10.7 ± 0.6 | 9.8 ± 2.4 | 10.5 ± 2.9 | – | |
| 19.0 ± 3.0 | – | 20.0 ± 2.6 | 22.0 ± 2.9 | 22.4 ± 4.7 | 22.8 ± 5.1 | 23.8 ± 4.6 | 20.3 ± 4.8 | – | |
| Doxorubicin | 0.01 | 0.02 | 0.03 | 0.05 | 0.04 | 0.03 | 0.02 | 0.04 | 0.04 |
The assay was done using three replicates and repeated four times. (–) IC50 > 50 µM.